#151461

Anti-FBW7 [FBOX 3a9/1]

Cat. #151461

Anti-FBW7 [FBOX 3a9/1]

Cat. #: 151461

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: F-box/WD repeat-containing protein 7 (FBW7, Cdc4)

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP ; WB

Reactivity: Human ; Mouse

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-FBW7 [FBOX 3a9/1]
  • Alternate name: F-Box And WD Repeat Domain Containing 7; F-Box Protein FBX3; SEL-1; Fbx3; HCdc4; FBW7; Hago; Homolog Of C Elegans Sel-1; F-Box Protein SEL-1; Archipelago Homolog; F-Box Protein FBW7; Archipelago; FBXO3; FBXW6; CDC4; FBW6; AGO
  • Research fields: Biochemistry;Cancer
  • Clone: FBOX 3a9/1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human ; Mouse
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: SCF (Skp, Cullin, F-box containing complex) ubiquitin ligases regulate the degradation of many proteins involved in the control of cell division and growth. F-box proteins are the SCF components that bind to substrates, and this binding is usually signaled by substrate phosphorylation. The FBW7/Cdc4 F-box protein was first recognized by its ability to bind cyclin E, and the SCF (FBW7) is now known to target c-Myc, c-Jun and Notch for degradation in addition to its role in cyclin E proteolysis. FBW7 thus negatively regulates several key oncoproteins. Accordingly, FBW7 is a tumor suppressor that is mutated in a wide spectrum of human cancers, and FBW7 functions as a haplo-insufficient tumor suppressor in mice.
  • Immunogen: Synthetic peptide of human sequence
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: F-box/WD repeat-containing protein 7 (FBW7, Cdc4)
  • Target background: SCF (Skp, Cullin, F-box containing complex) ubiquitin ligases regulate the degradation of many proteins involved in the control of cell division and growth. F-box proteins are the SCF components that bind to substrates, and this binding is usually signaled by substrate phosphorylation. The FBW7/Cdc4 F-box protein was first recognized by its ability to bind cyclin E, and the SCF (FBW7) is now known to target c-Myc, c-Jun and Notch for degradation in addition to its role in cyclin E proteolysis. FBW7 thus negatively regulates several key oncoproteins. Accordingly, FBW7 is a tumor suppressor that is mutated in a wide spectrum of human cancers, and FBW7 functions as a haplo-insufficient tumor suppressor in mice.

Applications

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Tu et al. 2013. PLoS One. 8(7):e68574. PMID: 23840897.
  • Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
  • Nateri et al. 2004. Science. 303(5662):1374-8. PMID: 14739463.
  • The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling.